
Study: Expert Panel Compiles Main Pediatric Impetigo Controversies
A recent literature review compiles a panel’s consensus and opinion on the main pediatric impetigo controversies.
A recent study in the
To find the controversies, a preliminary literature search was conducted using PubMed, MedLine, and Cochrane Library. Only literature published in English was included in the search.
Each controversy was discussed from a multidisciplinary perspective until reaching a consensus during the final meeting held November 2020. In order to reach consensus, total agreement among participants was needed. methicillin-resistant Staphylococcus aureus
The main controversies identified were:
- Impetigo caused by methicillin-resistant Staphylococcus aureus (MRSA) may be treated only with systemic antibiotic therapy.
- The association between topical and oral antibiotics represents the correct treatment of impetigo.
- Ozenoxacin has a potent antimicrobial activity against staphylococci and streptococci, as well as a rapid bactericidal activity and a low risk of antibiotic resistances.
- The efficacy of topical antibiotics is lower than that of the vast majority of oral antibiotics used for localized impetigo.
- In order to evaluate recovery, bacteriological results of skin swabs are crucial.
- The topical antibiotic treatment presents the disadvantage of limited absorption and the risk of sensitization developing contact dermatitis.
- The topical antibiotic treatment is strongly recommended only for children affected by localized non-bullous impetigo.
- Oral antibiotic treatment presents the disadvantage of major risk of systemic side effects (e.g., gastrointestinal side effects) and antibiotic resistances.
- Topical disinfectants represent the ideal strategy for the treatment of impetigo.
- To read the panels opinions pertaining to these controversies, see the
full literature review .
Reference:
1. Galli L, Novelli A, Ruggiero G, Stefani S, Fortina AB. Pediatric impetigo: an expert panel opinion about its main controversies. Journal of Chemotherapy. Published online August 18, 2021:1-7.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















